Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.

Clemens KratochwilKarl SchmidtAli Afshar-OromiehFrank BruchertseiferHendrik RathkeAlfred MorgensternUwe HaberkornFrederik L Giesel

Published in: European journal of nuclear medicine and molecular imaging (2017)

Dosimetry of 213Bi-PSMA-617 is in a range traditionally considered reasonable for clinical application. Nevertheless, compared to 225Ac-PSMA-617, it suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSMA-617 in dose-limiting organs than the physical half-life of 213Bi, rendering this nuclide as a second choice radiolabel for targeted alpha therapy of prostate cancer.

Keyphrases

pet ct
pet imaging
prostate cancer
positron emission tomography
cancer therapy
physical activity
mental health
radical prostatectomy
computed tomography
radiation therapy
monte carlo
radiation induced
drug delivery
smoking cessation
replacement therapy